- Privately-held biopharmaceutical company Biond Biologics has entered into an exclusive worldwide license agreement with Sanofi (NASDAQ:SNY), for the development and commercialization of BND-22, is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.
- Under the terms of the agreement, Biond will receive a $125M upfront payment in cash and will be entitled to receive more than $1B in development, regulatory, and sales milestones, as well as tiered double digit royalty payments.
- Biond will lead the first-in-human, phase 1a study of BND-22, evaluating its safety and tolerability as a single agent and in combination with approved cancer therapeutics as well as exploring potential associations between BND-22 anti-tumor activity and select tumor and blood-based biomarkers.
- Sanofi will assume clinical development and commercialization responsibilities thereafter.